Researchers at University College London (UCL) have pinpointed a sophisticated biological mechanism responsible for curtailing inflammatory responses, a discovery poised to revolutionize the development of novel therapeutic strategies for millions afflicted by chronic inflammatory ailments. Inflammation, a cornerstone of the immune system’s defense repertoire, is essential for combating pathogens and facilitating tissue repair following injury. However, its persistent activation can trigger detrimental effects on healthy tissues, contributing to a spectrum of debilitating conditions including arthritis, cardiovascular disease, and diabetes. While the initiation of inflammatory processes has been extensively studied, the precise signals and pathways that govern the transition from active defense to resolution and repair have remained less understood.
This groundbreaking research, detailed in the journal Nature Communications, illuminates the crucial role of a class of lipid-derived signaling molecules, specifically epoxy-oxylipins, in orchestrating the termination of inflammation. These molecules function as endogenous regulators, acting as a natural braking system for the immune response. They are instrumental in preventing the unchecked proliferation of intermediate monocytes, a subtype of white blood cells that, while beneficial in short-term inflammatory episodes for promoting healing, can exacerbate chronic inflammation if their numbers become excessive or their activity prolonged.
To meticulously examine this resolution process within a human context, the UCL team designed a study involving healthy volunteers. Participants were administered a minute dose of ultraviolet-inactivated Escherichia coli bacteria into their forearms. This controlled challenge, while incapable of initiating a true infection due to the bacteria’s inactivation, effectively elicited a transient inflammatory response, mirroring the physiological reactions observed after physical injury or exposure to pathogens, characterized by localized pain, redness, heat, and swelling.
The volunteers were then strategically assigned to different treatment arms to investigate the impact of modulating the epoxy-oxylipin pathway at various junctures of the inflammatory cascade. A specific pharmaceutical agent, GSK2256294, was administered to these participants; this compound is designed to inhibit the activity of soluble epoxide hydrolase (sEH). Under normal physiological conditions, sEH is responsible for the degradation of epoxy-oxylipins. Consequently, by blocking sEH, the drug facilitates an increase in the circulating levels of these protective lipid mediators within the body.
The findings from both prophylactic and therapeutic administration of the sEH inhibitor yielded remarkably consistent results. Elevated concentrations of epoxy-oxylipins, achieved through sEH inhibition, were directly correlated with a more rapid resolution of pain. Furthermore, the study observed a significant reduction in the abundance of intermediate monocytes, both in the bloodstream and within the affected tissue. These particular immune cells have been implicated in the perpetuation of inflammation and the pathological progression of inflammatory diseases. Interestingly, while the drug demonstrably influenced these deeper immune cellular dynamics, its impact on the more superficial visible signs of inflammation, such as redness and swelling, was less pronounced. This discrepancy suggests that the therapeutic intervention may be modulating fundamental immune signaling pathways even when overt external symptoms appear to persist.
Delving deeper into the molecular underpinnings of this phenomenon, the researchers investigated the precise mechanisms by which epoxy-oxylipins exert their anti-inflammatory effects. Their investigations revealed that a specific epoxy-oxylipin, identified as 12,13-EpOME, plays a pivotal role in attenuating the signaling cascade mediated by the p38 mitogen-activated protein kinase (MAPK) pathway. This particular pathway is known to be a key driver in the differentiation of monocytes into the intermediate form that is associated with sustained inflammatory activity. The research team rigorously validated these molecular interactions through in vitro laboratory experiments and further corroborated their findings in human volunteers who received a separate drug specifically designed to inhibit the p38 pathway directly.
Dr. Olivia Bracken, the study’s lead author and a researcher at the UCL Department of Ageing, Rheumatology and Regenerative Medicine, emphasized the significance of their discoveries. "Our findings unveil a naturally occurring regulatory pathway that effectively limits the expansion of detrimental immune cells, thereby facilitating a more expeditious resolution of inflammatory processes," she stated. "Targeting this specific mechanism holds the potential to yield safer therapeutic interventions that can restore immune equilibrium without compromising the body’s overall defense capabilities. Given that chronic inflammation represents a major global health challenge, this breakthrough opens a highly promising avenue for the development of next-generation therapies."
The conventional approach to managing inflammatory and autoimmune disorders often involves broad immunosuppression, which, while reducing inflammation, can unfortunately impair the body’s innate ability to fend off infections. The newly identified pathway offers an alternative paradigm: augmenting an intrinsic biological process that the body already employs to bring inflammation under control. Professor Derek Gilroy, the corresponding author and a professor in the UCL Division of Medicine, highlighted the novelty of this human-centric research. "This represents the inaugural study to meticulously map the activity of epoxy-oxylipins in humans during an inflammatory response," he commented. "By enhancing these beneficial fat-derived molecules, we can conceptualize and develop therapeutic agents that are significantly safer for the treatment of diseases driven by chronic inflammation." He further elaborated that the study’s direct relevance to autoimmune conditions is amplified by the use of a drug already approved for human use, suggesting its potential for repurposing to manage acute exacerbations of chronic inflammatory diseases, an area currently lacking in effective therapeutic options.
The focus on epoxy-oxylipins was motivated by compelling evidence from preclinical animal studies that indicated their capacity to mitigate inflammation and alleviate pain. However, their precise role in human physiology remained largely elusive. In contrast to more widely recognized inflammatory mediators such as histamine and cytokines, epoxy-oxylipins are part of a signaling system that has been comparatively less explored. Scientists had hypothesized that this pathway might facilitate the immune system’s natural transition from an active inflammatory state toward a phase of recovery and repair. The current human study provides robust, direct empirical support for this hypothesis.
The implications of these findings are substantial, potentially paving the way for the initiation of clinical trials to evaluate the efficacy of sEH inhibitors in managing a range of chronic inflammatory conditions, including rheumatoid arthritis and cardiovascular disease. Dr. Bracken suggested specific applications, noting, "For instance, rheumatoid arthritis, an autoimmune condition where the immune system mistakenly attacks the joint lining, could potentially benefit. sEH inhibitors might be investigated in conjunction with existing treatments to determine if they can help prevent or decelerate the joint damage characteristic of this disease." Rheumatoid arthritis is characterized by the immune system’s misguided assault on the tissues surrounding the joints, leading to pain, swelling, stiffness, and potentially irreversible damage.
Dr. Caroline Aylott, Head of Research Delivery at Arthritis UK, underscored the profound impact of arthritis pain on an individual’s life. "The pain associated with arthritis can profoundly affect mobility, cognitive function, sleep patterns, and overall emotional well-being, as well as the ability to engage in social activities," she remarked. "Pain is an incredibly complex experience, influenced by numerous factors, and we recognize that each individual’s pain perception is unique. This underscores the critical importance of investing in research like this, which deepens our understanding of the underlying causes and contributing factors to people’s experience of pain." She expressed enthusiasm for the study’s results, which have identified a natural process that could potentially halt inflammation and pain, holding promise for the development of novel pain management strategies for individuals living with arthritis.
*Intermediate monocytes are a type of white blood cell crucial for combating infections and facilitating tissue repair. In brief inflammatory episodes, they play a role in orchestrating the immune response and promoting recovery. However, their sustained presence or excessive proliferation can lead to a persistently activated immune system, thereby contributing to chronic inflammation.
The research was generously supported by Arthritis UK and involved a collaborative effort among researchers from University College London, King’s College London, the University of Oxford, Queen Mary University of London, and the National Institute of Environmental Health Sciences in the USA.
About the Author
